Methafly 400 Tablet (Metronidazole 400mg) in PCD Pharma Franchise in Kolkata

Methafly 400 Tablet (Metronidazole 400mg) in Pharmaceutical Manufacturing Company in Ahmedabad

Methafly 400 Tablet (Metronidazole 400mg) in General Medicine Pharma Franchise in Lucknow

Metofoli 400 Tablet (Metronidazole 400mg) in Pharma Distributors & Suppliers in Chennai

Methafly 400 Tablet (Metronidazole 400mg) in Pharma Export Company in Mumbai
Methafly 400 Tablet (Metronidazole 400mg) in Pharma Franchise Opportunity in Jaipur

Home/Products /metronidazole-400-mg-tablet

About the Product

Description


Methafly 400 Tablet contains Metronidazole 400 mg, an antiprotozoal and antibacterial agent used to treat a wide range of infections caused by anaerobic bacteria and certain parasites. It works by disrupting the DNA structure of microbial cells, inhibiting nucleic acid synthesis, which leads to the death of the pathogens. Metronidazole is particularly effective in treating infections of the gastrointestinal tract, genitourinary tract, skin, joints, and respiratory system. It is also widely used in the management of bacterial vaginosis, pelvic inflammatory disease, amoebiasis, giardiasis, and infections caused by Clostridium difficile. Metofoli 400 is an essential medicine in both outpatient and hospital settings due to its broad-spectrum efficacy against anaerobic organisms. Its oral formulation allows for easy and convenient administration, making it a go-to treatment for a variety of infectious conditions.

Common side effects of Metofoli 400 Tablet include nausea, metallic taste in the mouth, loss of appetite, abdominal discomfort, and headache. Less commonly, it may cause dizziness, dark-colored urine, dry mouth, or vomiting. Rare but serious side effects include seizures, peripheral neuropathy (tingling or numbness in hands or feet), and allergic reactions such as rash or swelling. Prolonged use should be avoided unless advised, as it may lead to fungal overgrowth or secondary infections.

Methafly 400 Tablet is indicated for the treatment of anaerobic bacterial infections and protozoal infections. Specific indications include amoebiasis (intestinal and hepatic), giardiasis, trichomoniasis, bacterial vaginosis, pelvic infections, pseudomembranous colitis, dental infections, and surgical prophylaxis where anaerobes are likely. It is also used as part of combination therapy for Helicobacter pylori eradication in peptic ulcer disease.

Methafly 400 Tablet should be taken exactly as prescribed by a healthcare professional. It should not be consumed with alcohol during the course of treatment and for at least 48 hours after the last dose, as it may cause a disulfiram-like reaction (nausea, vomiting, flushing, and headache). Use with caution in patients with liver disease, central nervous system disorders, or a history of blood dyscrasias. Pregnant and breastfeeding women should use this medication only under medical supervision. Do not discontinue the medicine early, even if symptoms improve, to avoid recurrence or resistance.

Store Methafly 400 Tablet in a cool, dry place below 30°C. Protect from moisture, direct sunlight, and heat. Keep the medication in its original packaging and out of reach of children. Do not use the tablet beyond its expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Metronidazole 400 mg Tablets in the PCD pharma franchise market?

Metronidazole Tablets (400 mg) have strong demand in the anti-infective and gastroenterology segment, making them a high-volume product for pharma distributors, wholesalers, and franchise partners. It is widely used for anaerobic bacterial infections, gastrointestinal infections, dental infections, and protozoal diseases, ensuring consistent prescription-based demand.

Why should medical distributors include Metronidazole 400 mg Tablets in their product range?

Medical distributors and agencies benefit from the high-frequency use in infection management across multiple specialties. Effective against anaerobic bacteria and protozoal infections Commonly prescribed for amoebiasis, giardiasis, dental infections, and abdominal infections Widely used by general physicians, dentists, and surgeons Important component in combination antibiotic therapies Strong demand in both hospital and retail pharmacy markets Affordable and widely accepted anti-infective medicine This makes it a fast-moving and essential GI and infection control product.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Metronidazole 400 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and franchise partners benefit from steady prescription flow in infection cases, strong hospital and dental demand, repeat usage in GI infections, and stable year-round sales in the anti-infective segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete anti-infective product portfolio access to build a strong presence in the gastrointestinal and infection treatment market.